Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Clancy

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Methodsx|August 26, 2021
Seasonality, mediation and comparison (SMAC) methods to identify influences on lung function declineEmrah Gecili, Anushka Palipana, Cole Brokamp, et al.
The Science of the Total Environment|February 7, 2022
Seasonal variation of lung function in cystic fibrosis: longitudinal modeling to compare a Midwest US cohort to international populationsEmrah Gecili, Cole Brokamp, Anushka Palipana, et al.
Annals of the American Thoracic Society|July 10, 2020
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical TrialScott D Sagel, Umer Khan, Sonya L Heltshe, et al.
Expert Review of Respiratory Medicine|April 9, 2020
Influences of environmental exposures on individuals living with cystic fibrosisRhonda Szczesniak, Jessica L Rice, Cole Brokamp, et al.
Chembiochem : a European Journal of Chemical Biology|August 1, 2015
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click ChemistryChandrima Sinha, Weiqiang Zhang, Chang Suk Moon, et al.
American Journal of Respiratory Cell and Molecular Biology|March 10, 2007
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsJohn P Clancy, Steven M Rowe, Zsuzsa Bebok, et al.
Chest|February 11, 2004
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trialRichard B Moss, David Rodman, L Terry Spencer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 15, 2024
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trialAlex H Gifford, Katherine Odem-Davis, Margaret Kloster, et al.
Pediatric Research|May 6, 2010
Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn pigletAshish R Kurundkar, Cheryl R Killingsworth, R Britt McIlwain, et al.
Plos One|August 8, 2013
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutationSteven M Rowe, Bo Liu, Aubrey Hill, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Methodsx|August 26, 2021
Seasonality, mediation and comparison (SMAC) methods to identify influences on lung function declineEmrah Gecili, Anushka Palipana, Cole Brokamp, et al.
The Science of the Total Environment|February 7, 2022
Seasonal variation of lung function in cystic fibrosis: longitudinal modeling to compare a Midwest US cohort to international populationsEmrah Gecili, Cole Brokamp, Anushka Palipana, et al.
Annals of the American Thoracic Society|July 10, 2020
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical TrialScott D Sagel, Umer Khan, Sonya L Heltshe, et al.
Expert Review of Respiratory Medicine|April 9, 2020
Influences of environmental exposures on individuals living with cystic fibrosisRhonda Szczesniak, Jessica L Rice, Cole Brokamp, et al.
Chembiochem : a European Journal of Chemical Biology|August 1, 2015
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click ChemistryChandrima Sinha, Weiqiang Zhang, Chang Suk Moon, et al.
American Journal of Respiratory Cell and Molecular Biology|March 10, 2007
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsJohn P Clancy, Steven M Rowe, Zsuzsa Bebok, et al.
Chest|February 11, 2004
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trialRichard B Moss, David Rodman, L Terry Spencer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 15, 2024
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trialAlex H Gifford, Katherine Odem-Davis, Margaret Kloster, et al.
Pediatric Research|May 6, 2010
Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn pigletAshish R Kurundkar, Cheryl R Killingsworth, R Britt McIlwain, et al.
Plos One|August 8, 2013
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutationSteven M Rowe, Bo Liu, Aubrey Hill, et al.
Pageof 13